XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2019 $ 1,160     $ 4   $ 426,426 $ (425,270)
Balance (in shares) at Dec. 31, 2019   1,959   3,880,588      
Stock-based compensation 12         12  
Net loss (1,087)           (1,087)
Balance at Mar. 31, 2020 85     $ 4   426,438 (426,357)
Balance (in shares) at Mar. 31, 2020   1,959   3,880,588      
Balance at Dec. 31, 2019 1,160     $ 4   426,426 (425,270)
Balance (in shares) at Dec. 31, 2019   1,959   3,880,588      
Net loss (4,654)            
Balance at Sep. 30, 2020 2,621     $ 5   432,540 (429,924)
Balance (in shares) at Sep. 30, 2020   1,954   4,591,415      
Balance at Dec. 31, 2019 1,160     $ 4   426,426 (425,270)
Balance (in shares) at Dec. 31, 2019   1,959   3,880,588      
Balance at Dec. 31, 2020 3,031     $ 7   436,535 (433,511)
Balance (in shares) at Dec. 31, 2020   1,954   6,749,028      
Balance at Mar. 31, 2020 85     $ 4   426,438 (426,357)
Balance (in shares) at Mar. 31, 2020   1,959   3,880,588      
Stock-based compensation 43         43  
Issuance of common stock for exercise of warrants 366         366  
Issuance of common stock for exercise of warrants (in shares)       162,500      
Reclassification of warrant liabilities 4,264         4,264  
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics 381         381  
Issuance of common stock for in process research and development acquired (in share)       230,769      
Net loss (1,839)           (1,839)
Balance at Jun. 30, 2020 3,300     $ 4   431,492 (428,196)
Balance (in shares) at Jun. 30, 2020   1,959   4,273,857      
Stock-based compensation 94         94  
Conversion of Convertible Preferred Stock into common stock (share)     (5)   37    
Issuance of common stock for exercise of warrants 715     $ 1   714  
Issuance of common stock for exercise of warrants (in shares)       317,521      
Reclassification of warrant liabilities 240         240  
Net loss (1,728)           (1,728)
Balance at Sep. 30, 2020 2,621     $ 5   432,540 (429,924)
Balance (in shares) at Sep. 30, 2020   1,954   4,591,415      
Balance at Dec. 31, 2020 3,031     $ 7   436,535 (433,511)
Balance (in shares) at Dec. 31, 2020   1,954   6,749,028      
Stock-based compensation 107         107  
Sale of common stock, net of offering cost 7,078     $ 2   7,076  
Sale of common stock, net of offering cost (in shares)       2,534,879      
Conversion of Convertible Preferred Stock into common stock (share)     (2)   118    
Issuance of common stock for exercise of warrants 2,017     $ 1   2,016  
Issuance of common stock for exercise of warrants (in shares)       896,500      
Net loss (2,720)           (2,720)
Balance at Mar. 31, 2021 9,513     $ 10   445,734 (436,231)
Balance (in shares) at Mar. 31, 2021   1,952   10,180,525      
Balance at Dec. 31, 2020 3,031     $ 7   436,535 (433,511)
Balance (in shares) at Dec. 31, 2020   1,954   6,749,028      
Net loss (9,244)            
Balance at Sep. 30, 2021 14,755     $ 15   457,495 (442,755)
Balance (in shares) at Sep. 30, 2021   1,952   15,360,025      
Balance at Mar. 31, 2021 9,513     $ 10   445,734 (436,231)
Balance (in shares) at Mar. 31, 2021   1,952   10,180,525      
Stock-based compensation 138         138  
Sale of common stock, net of offering cost 5,094     $ 2   5,092  
Sale of common stock, net of offering cost (in shares)       1,907,000      
Net loss (2,800)           (2,800)
Balance at Jun. 30, 2021 11,945     $ 12   450,964 (439,031)
Balance (in shares) at Jun. 30, 2021   1,952   12,087,525      
Stock-based compensation 180         180  
Sale of common stock, net of offering cost 6,354     $ 3   6,351  
Sale of common stock, net of offering cost (in shares)       3,272,500      
Net loss (3,724)           (3,724)
Balance at Sep. 30, 2021 $ 14,755     $ 15   $ 457,495 $ (442,755)
Balance (in shares) at Sep. 30, 2021   1,952   15,360,025